NDC product
Abacavir and Lamivudine
NDC 33342-440 · Macleods Pharmaceuticals Limited
Key facts
| Product NDC | 33342-440 |
|---|---|
| Proprietary name | Abacavir and Lamivudine |
| Nonproprietary name | Abacavir and Lamivudine |
| Substances | ABACAVIR SULFATE, LAMIVUDINE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Macleods Pharmaceuticals Limited |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA212663 |
| Pharmacologic classes | Cytochrome P450 1A1 Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| Marketing start | Dec 20, 2024 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: